Haemacure Corporation
Medical Devices & Tech  Advamed Member
2001 University St.,Suite 430
Montreal, Quebec H3A 2A6 Canada
phone: (1) 514 282 3350
fax: (1) 514 282 3358
Symbol HAE
Exchange TSX
Founded 0
Employees
www.haemacure.com
Research Sector Medical Devices & Tech
Summary Description
Surgical devices, adhesives, and biomaterials for surgical wound care
Management
Joseph Galli, Chairman and Chief Executive Officer; Christian hours, Ph.D, Vice President, Quality and Technical Services; Me Gilles Lemieux, B.A.A., LLL, Secretary; Lyne Pare, CA, Director, Finance and Administration; Marc Paquin, President
Ownership
Financials Mkt Cap :1


* numbers in thousands

 
Keywords
wound, woundcare, Surgery Products, Surgery, hemostat, plasma proteins
http://www.haemacure.com/en/images/logo.jpg

Comment | Printable Version | Jan. 03, 2009
If you work for Haemacure Corporation and want to update this profile, click here

Description
Haemacure Corporation is a specialty bio-therapeutics company developing high-value human biological adhesives, therapeutic proteins, and hemostats for commercialization. Haemacure's research and development effort is driven by its proprietary plasma protein extraction technology used to develop next-generation products, including surgical hemostats (instruments to prevent flow of blood from an open blood vessel).
Products / Services
Haemacure's lead product candidate, Hemaseel(R) HMN, is a human-derived fibrin sealant in late-stage clinical development. Haemacure's second product candidate is a hemostat consisting of human thrombin, a component of its fibrin sealant. Product development activities focus on surgical hemostats-and their combinations with biomaterials-as well as drug delivery in select therapeutic areas.
Technology / Differentiation
Haemacure's technologies utilize fibrinogen and thrombin from human plasma to arrest bleeding, seal tissues and act as an adjunct to wound healing. The synthesis of Haemacure products from human plasma, and not from bovine components, precludes any cross-species immunological risks and disease transmission.
Market / Customers
Haemacure's fibrin sealant and hemostats have numerous applications in the bio-surgical market, which is expected to grow at double-digit rates until 2015 to reach a U.S. market value of $1.5 billion.
Status
Haemacure projects to have patients undergo surgery with its fibrin sealant as part of a clinical trial early in 2009. It will commercially launch its fibrin sealant in late 2010-early 2011.


2009-01-07-881